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aHUS should be considered. The terminal complement 
inhibitor eculizumab should be initiated for all patients 
with conirmed diagnosis of aHUS, with or without a 
comorbid CAC.
Keywords Complement · Thrombotic microangiopathy · 
Pregnancy · Hypertension · Kidney transplantation
Introduction
Thrombotic microangiopathy (TMA) is a life-threatening 
syndrome of systemic microvascular occlusions and is 
characterized by sudden or gradual onset of thrombocy-
topenia, microangiopathic hemolytic anemia, and renal or 
other end-organ damage [1, 2]. TMA has been associated 
with diverse diseases and syndromes, such as systemic 
infections, cancer, pregnancy complications [e.g. preec-
lampsia, eclampsia, HELLP (hemolysis, elevated liver 
enzymes, low platelet count) syndrome], autoimmune dis-
orders [e.g. systemic lupus erythematosus (SLE), systemic 
sclerosis, antiphospholipid syndrome], hematopoietic stem-
cell or organ transplantation, and severe hypertension [1].
The etiologies of TMA also include atypical hemolytic 
uremic syndrome (aHUS) [1], a rare, progressive, life-
threatening form predominantly caused by dysregulation of 
the complement alternative pathway [3]. aHUS can mani-
fest at any age. While approximately 80 % of patients pre-
sent with thrombocytopenia, microangiopathic hemolytic 
anemia, and renal impairment [4], onset may be more grad-
ual in other patients [5]. Because aHUS can afect multiple 
vascular beds [6], extrarenal manifestations occur in up to 
48 % of patients, with frequent neurologic and cardiovascu-
lar involvement [7–10].
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Patients with aHUS who are untreated remain at lifelong 
risk of renal impairment, end-stage renal disease, extrare-
nal complications, and premature death [4, 9]. Manage-
ment with plasma exchange/plasma infusion (PE/PI) may 
improve hematologic parameters temporarily [11, 12] 
but not long-term outcomes [4]. The eicacy and safety 
of eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., 
Cheshire, CT, USA), a terminal complement inhibitor and 
the only approved treatment for aHUS [13, 14], were irst 
established in two prospective, multicenter clinical stud-
ies [15, 16], followed by prospective, multicenter studies 
in pediatric [17] and adult [18] populations. Eculizumab 
therapy was demonstrated to inhibit complement-mediated 
TMA and improve hematologic parameters, renal function, 
and quality of life [15, 17, 18].
According to the “multiple-hit” hypothesis [19], aHUS 
is a consequence of both genetic predisposition to alterna-
tive complement dysregulation as well as the occurrence of 
events or conditions that may precipitate TMA by activat-
ing complement and/or damaging the endothelium [19, 20]. 
Complement-amplifying conditions (CACs), such as preg-
nancy complications (preeclampsia, HELLP), autoimmune 
diseases and others, may be comorbid with aHUS, unmask 
a previously undiagnosed case, or lead to a misdiagnosis 
[3, 21–23]. Malignant hypertension (MHT) is another CAC 
that may precipitate aHUS or occur secondary to aHUS 
[21], potentially confounding the diagnosis. In this review, 
we describe case reports that demonstrate the onset of 
aHUS in the setting of CACs. We also review the evidence 
for a number of CACs, including pregnancy complications, 
MHT, autoimmune diseases, transplantation, infections, 
and drugs, and the overlap of these disorders with aHUS. 
Finally, we present an algorithm for diagnosis and treat-
ment of aHUS in the setting of CACs (Fig. 1) [5].
Case reports
Case 1
A 33-year-old Hispanic woman developed abruptio pla-
centae leading to fetal death at 33 weeks of gestation. She 
underwent cesarean section and hysterectomy, and a sub-
sequent exploratory laparotomy. The patient had exten-
sive blood loss and received numerous transfusions. She 
developed thrombocytopenia [39 × 109/L (normal range 
150–350 × 109/L)], microangiopathic hemolytic anemia 
[hemoglobin level 6.7  g/dL (normal range 14.0–17.5  g/
dL)]; lactate dehydrogenase (LDH) level, 2670  U/L (nor-
mal range at institution, 100–200 U/L); haptoglobin level, 
5.8  mg/dL (normal range at institution, 26–185  mg/dL); 
numerous schistocytes on a blood smear, and renal fail-
ure [serum creatinine level, 6.0  mg/dL (normal range 
0.6–1.2  mg/dL)] necessitating initiation of hemodialysis. 
The ibrinogen level as well as prothrombin and partial 
thromboplastin times were normal. ADAMTS13 (a disin-
tegrin and metalloproteinase with a thrombospondin type 
1 motif, member 13) activity testing was ordered and PE 
Fig. 1  Management algorithm 
for patients with CACs and 
TMA. ADAMTS13 a disintegrin 
and metalloproteinase with a 
thrombospondin type 1 motif, 
member 13, aHUS atypical 
hemolytic uremic syndrome, 
CAC complement-amplifying 
condition, STEC Shiga-like 
toxin-producing Escherichia 
coli, TMA thrombotic micro-
angiopathy, TTP thrombotic 
thrombocytopenic purpura. aThe 
diferential diagnosis section of 
the algorithm has been adapted 
from [5]
Patient with an 
identified CAC
presents with TMA
Adequately treat the CAC
Reassess during additional 
disease manifestations or 
symptoms
ADAMTS13 activity <5%
ADAMTS13 activity ≥5% & 
STEC test (-)
STEC test (+)
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was initiated. The patient showed minimal improvement 
in hematologic parameters (hemoglobin level, 7.0  g/dL; 
platelet count, 42 × 109/L) and no improvement in renal 
function (dialysis dependent) after ive daily PEs, and the 
ADAMTS13 activity level was 56 %. Following diagnosis 
of aHUS, PE was discontinued. After the discontinuation 
of PE, the patient was vaccinated against meningococcus, 
antibiotic prophylaxis was started, and eculizumab therapy 
was initiated. Two weeks later, dialysis was discontinued. 
Laboratory tests showed a platelet count of 147 × 109/L, 
hemoglobin level of 8.8 mg/dL, and serum creatinine level 
of 3.4  mg/dL. At last follow-up after 27 weeks of eculi-
zumab therapy, platelet count (198 × 109/L), hemoglobin 
level (13.0  g/dL), and serum creatinine level (0.9  mg/dL) 
were normal. The patient remains on ongoing eculizumab 
therapy.
Case 2
A 43-year-old Caucasian woman with a history of migraine 
headaches since childhood presented with severe headaches 
and visual impairment lasting for several days. The exami-
nation showed a blood pressure of 300/185 mmHg result-
ing in immediate hospitalization. Fundoscopic examination 
revealed papilledema, and a subsequent cerebral magnetic 
resonance tomography showed alterations consistent with 
posterior reversible encephalopathy syndrome. Laboratory 
tests including hemoglobin level of 10.8 g/dL, LDH level 
of 447  U/L (normal range at institution, <250  U/L) and 
schistocytes on a blood smear revealed microangiopathic 
hemolytic anemia; the platelet count was normal. Acute 
kidney injury [serum creatinine level, 3.4  mg/dL (normal 
range at institution, 0.5–1.0 mg/dL); proteinuria] also was 
evident. PE was initiated because thrombotic thrombocy-
topenic purpura (TTP) could not be ruled out initially, but 
was discontinued after the ADAMTS13 activity was deter-
mined to be 64 %. The patient’s hypertension was managed 
with intravenous and oral antihypertensive medications 
resulting in the resolution of neurological symptoms. Stool 
examination showed no Shiga toxin-producing Escherichia 
coli (STEC). A kidney biopsy revealed severe oblitera-
tive arteriolosclerosis, ischemic glomerular collapses, and 
extensive acute tubular injury. Together with typical signs 
of hypertensive retinopathy and echocardiographic evi-
dence of hypertensive heart disease, the patient was consid-
ered to have MHT. However, despite adequate blood pres-
sure control and resolution of hemolysis (LDH, 163 U/L), 
there was no improvement in anemia (hemoglobin, 10.7 g/
dL) and renal function (serum creatinine level, 3.3 mg/dL) 
over approximately 5.5 weeks from presentation. Therefore, 
aHUS was diagnosed with MHT as a presenting sign. No 
complement gene mutations were identiied. After menin-
gococcal vaccination and antibiotic prophylaxis, initiation 
of eculizumab therapy resulted in gradual improvement 
of renal function. After 9 months of therapy, the patient’s 
hemoglobin level was 12.2 g/dL and serum creatinine level 
was stable at 2.1 mg/dL. After 11 months, the hemoglobin 
and serum creatinine levels were 12.9 g/dL and 2.0 mg/dL, 
respectively. The patient discontinued from eculizumab 
therapy after 1 year.
Case 3
A 37-year-old Caucasian female hemodialysis patient with 
a 14-month history of end-stage renal disease due to recur-
rent pyelonephritis underwent living-related donor kidney 
transplantation. Excellent graft function was noted imme-
diately following the surgery, and the serum creatinine 
level decreased to 0.9  mg/dL. Over the subsequent days, 
however, urine output gradually decreased and serum cre-
atinine levels increased (1.85  mg/dL on day 5 post-sur-
gery). Humoral rejection was suspected (increasing titer 
of donor-speciic antibodies), and the patient was treated 
with high-dose corticosteroids and PI. However, the patient 
developed anuria. Doppler ultrasound showed near-absent 
graft perfusion. In addition, TMA was suggested by labora-
tory values including the presence of schistocytes, platelet 
count of 33 × 109/L, hemoglobin level of 11.7 g/dL, LDH 
of 675 U/L (normal range at institution, <250 U/L), serum 
creatinine of 3.5 mg/dL, and heavy proteinuria (6701 mg/g 
creatinine). The patient was started on hemodialysis 
because of volume overload and progressive renal dysfunc-
tion. On post-transplant day 8, a diagnosis of aHUS was 
made. Eculizumab therapy, along with antibiotic prophy-
laxis for meningococcal infection, was initiated, leading to 
gradual resolution of hemolysis and improved renal func-
tion. A renal allograft biopsy revealed TMA consistent 
with the clinical diagnosis of aHUS. Immunostaining dem-
onstrated C4d staining of peritubular capillaries consistent 
with humoral rejection. Immunoabsorption was performed 
for 3 days followed by two doses of intravenous immu-
noglobulins. Eculizumab treatment was continued with 
improvement in renal function without the need for further 
renal replacement therapy. The patient received meningo-
coccal vaccination following discharge. At a follow-up of 6 
months, platelet count continues to be stable at 213 × 109/L, 
hemoglobin level at 11.9 g/dL, LDH level at 273 U/L, and 
serum creatinine level at 1.7  mg/dL. The patient contin-
ues to receive eculizumab therapy. Genetic testing did not 
reveal any complement gene mutations.
Discussion
These case reports illustrate aHUS in the setting of 
three CACs: pregnancy complications, MHT, and renal 
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transplantation. In all three cases, a CAC preceded the 
onset of TMA. Importantly, the standard management of 
the individual CAC (i.e. cesarean section and subsequent 
hysterectomy after pregnancy complications, antihyperten-
sive medications for MHT, and corticosteroid therapy for 
humoral allograft rejection) did not resolve TMA. Each 
patient had a thorough evaluation for potential underlying 
causes of TMA. After prompt diagnosis of TMA and rec-
ognition of aHUS in each case, treatment with eculizumab 
was associated with improvement in both hematologic 
parameters and renal function.
Accumulating evidence shows that patients with under-
lying complement dysregulations are particularly prone to 
develop TMA when experiencing a CAC. Chronic com-
plement dysregulation, both in aHUS and other disorders, 
leaves patients predisposed to TMA [24]. When patients 
are unable to regulate complement, onset or exacerbation 
of CACs may precipitate aHUS or cause additional mani-
festations, resulting in persistent TMA despite treatment 
of CAC symptoms [25]. Findings from a large observa-
tional study of patients with aHUS showed that 69 % of the 
patients had their irst TMA manifestations while experi-
encing a CAC [9].
Proper diagnosis may be particularly challenging in 
the setting of aHUS and CACs due to overlapping comor-
bidities [1]. Patients may not necessarily present with 
the classic triad of microangiopathic hemolytic anemia, 
thrombocytopenia, and renal impairment [3]; in particular, 
thrombocytopenia may be absent or mild in MHT [26]. In 
a large observational study of patients with aHUS, 16 % of 
patients did not have thrombocytopenia at disease onset 
[4]. In the described case with MHT, the patient had a nor-
mal platelet count at presentation. It is possible that some 
patients may develop thrombocytopenia relative to earlier 
laboratory tests, although all values may remain in the nor-
mal range. Elevated LDH levels and the presence of schis-
tocytes may also be considered important diagnostic fea-
tures of microangiopathic hemolytic anemia [5].
Review of CACs
Pregnancy complications
TMA occurs in approximately 1 per 25,000 pregnancies 
[27]. Pregnancy-related aHUS (P-aHUS) may account for 
approximately 7 % of total aHUS cases [9] and up to 20 % 
of cases in adult females [4, 28]. Complement activation 
may be augmented during pregnancy, when the placenta 
may be subject to attack by the complement and immune 
system [28]. In addition, the complement pathway may be 
activated postpartum due to maternal circulation of fetal 
cells, infections, and hemorrhage [28]. Recently, increased 
complement activation was identiied in a subset of women 
with preeclampsia and HELLP syndrome [29].
In addition to microangiopathic hemolytic anemia, 
thrombocytopenia, and renal insuiciency, general signs 
and symptoms of P-aHUS may include fatigue, headache, 
nausea, and vomiting. Diagnosis may be diicult because 
of similarities between P-aHUS and more common preg-
nancy complications such as preeclampsia and HELLP [27, 
30]. A recent study of 21 women with P-aHUS showed that 
most cases occurred postpartum and during second preg-
nancies [28]. Clinical conditions could rapidly deteriorate, 
resulting in poor maternal outcomes [27]. Hypertension 
and chronic kidney disease were frequent long-term com-
plications [27]. End-stage renal disease occurred in 76 % of 
patients. In severe cases, death may occur within hours to 
days after the onset of P-aHUS [31].
P-aHUS case reports were irst published more than 40 
years ago [32]. Delmas et al. [33] were the irst to show the 
beneicial efects of eculizumab on hematologic and renal 
parameters in a patient with postpartum aHUS. More recent 
case studies also documented the eicacy of eculizumab in 
the treatment of P-aHUS, including normalization of hema-
tologic parameters and renal function (Table 1) [33–41].
Emerging evidence shows the safety of eculizumab dur-
ing pregnancy despite potential placental transfer to the 
fetus. In a study of 75 pregnancies in 61 women with par-
oxysmal nocturnal hemoglobinuria (PNH) treated with ecu-
lizumab during pregnancy and postpartum, fetal mortality 
rates were not increased [38]. In these patients, eculizumab 
was present at low levels in 35 % of cord blood samples, 
but not in breast milk [42]. Similarly, recently reported case 
series involving pregnant PNH patients treated with eculi-
zumab demonstrated low levels of the drug in cord blood, 
but not in breast milk [43, 44]. There were no adverse 
efects on the newborns noted.
Malignant hypertension
MHT can be associated with TMA [45, 46]. Many patients 
with aHUS irst present with hypertension, potentially 
with high severity and/or MHT [7, 9, 10]. In a retrospec-
tive study of 45 children with aHUS, 71 % presented with 
hypertension [10]. In a large observational study, 8 % of 
patients with aHUS also had MHT [9].
The role of the endothelium as a pathogenic link 
between MHT and aHUS was recently reviewed [47]. TMA 
may occur following luid shear stress on endothelial cells 
and subsequent vascular injury (i.e. ibrinoid necrosis, 
thrombosis, and luminal narrowing), leading to red blood 
cell fragmentation and platelet consumption [45, 46, 48]. 
Aldosterone has been implicated as a potential mediator 
of vascular endothelial damage in hypertension [21, 49, 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































be higher in MHT patients with TMA versus those without 
TMA [21]. In addition, hypertensive crises are known to be 
prothrombotic, leading to platelet aggregation, thrombin 
generation, and ibrinolysis [51].
Patients with MHT may present with microangiopathic 
hemolytic anemia, renal impairment, and thrombocytope-
nia [46], although the latter may be modest and/or resolve 
quickly [26, 52]. Diferentiation between MHT-associated 
TMA and TTP may be particularly diicult because both 
are associated with neurologic symptoms; however, renal 
dysfunction may be more common in TMA caused by 
MHT [26]. Prior history of hypertension and/or relatively 
high arterial pressure, signs of hypertensive heart disease, 
relatively high platelet count, and retinopathy are sugges-
tive of MHT-associated TMA [26]. To that end, imaging 
techniques may be useful in conirming congestive heart 
disease and/or neurologic involvement due to MHT.
Without proper diagnosis and adequate treatment, 
patients with aHUS and hypertension and/or MHT may 
have severe symptoms and poor outcomes, including 
death [53, 54]. Because standard therapies for MHT do not 
address underlying complement dysregulation, TMA may 
persist despite such treatment. In a retrospective analysis 
of 21 patients with TMA and severe/malignant hyperten-
sion, 86 % did not recover normal renal function despite 
antihypertensive therapy [55]. It has been proposed that 
a diagnosis of aHUS should be suspected in patients with 
diicult-to-control MHT who demonstrate persistent TMA 
[52]. In such patients, treatment with eculizumab should 
be considered. Indeed, case studies have demonstrated the 
eicacy and safety of eculizumab, with or without antihy-
pertensive agents, in the treatment aHUS in patients with 
MHT (Table 1) [52, 56–62].
Renal transplantation
Recurrent and de novo aHUS following renal transplan-
tation have been reviewed in detail previously [5, 63]. 
The availability of eculizumab has substantially changed 
the landscape of renal transplantation in patients with 
aHUS [5, 63]. In the pre-eculizumab era, renal transplan-
tation in aHUS was associated with poor graft survival 
and high rates of disease recurrence [64]. In contrast, a 
large series of 22 patients demonstrated that eculizumab 
therapy was efective in preventing and treating aHUS 
recurrence post-transplant [65]. Patients at high risk for 
recurrence are now candidates for renal transplantation 
[5]. Additionally, living-non-related donor transplan-
tation may now be considered for certain patients [63]. 
Expert groups recommend that patients, especially with 
moderate or high risk for disease recurrence following 
renal transplantation, receive prophylactic eculizumab 
therapy [5, 63]. Eculizumab should also be considered for 
patients with de novo aHUS following renal transplanta-
tion [5].
Autoimmune diseases
Systemic lupus erythematosus SLE is characterized by the 
formation of immune complexes that activate complement, 
leading to cellular injury [66]. Dysregulation of the termi-
nal complement activation has been implicated in the patho-
genesis and prognosis of SLE and lupus nephritis [66–68]. 
Complement gene mutations have been identiied in patients 
with SLE and are associated with disease susceptibility [69] 
and earlier disease onset [69, 70]. In patients with SLE, 
TMA is associated with increased SLE activity, intercur-
rent infections [71], reduced long-term renal function, and 
poor overall survival [72–76]. Although TMA is typically 
Coombs-negative [5], patients with SLE and aHUS may 
have positive Coombs tests [77].
Recent case studies of SLE comorbid with aHUS have 
reported varying outcomes with standard SLE therapies 
(e.g. cyclophosphamide, high-dose steroids, mycophenolate 
mofetil). Patients may have slow recovery [78], no response 
[79–81], or remain dialysis-dependent [82]. Findings from 
reports of patients with SLE and aHUS treated with eculi-
zumab have demonstrated the terminal complement inhibi-
tor to be well tolerated and associated with improvement in 
symptoms, hematologic laboratory values, and renal func-
tion (Table 1) [79, 80, 83].
Scleroderma Progressive scleroderma, or systemic scle-
rosis, can be complicated by chronic kidney disease asso-
ciated with hypertension and mild proteinuria as well as 
by scleroderma renal crisis (SRC). SRC is the most severe 
form of renal disease in progressive scleroderma and carries 
a high mortality. SRC manifests as MHT, TMA, and rapid 
renal failure [84]. Diagnosis can be complicated by the lack 
of skin changes in some cases making renal histology and 
serology results the primary basis for appropriate diagno-
sis [85]. The pathogenesis of progressive scleroderma and 
its relation to aHUS is not well understood; it is believed 
that systemic vasoconstriction leads to ischemic injury and 
organ dysfunction [86].
Several cases of scleroderma-related aHUS have been 
reported in the literature [86–90]. Overall, outcomes were 
poor, including death within months of onset in one case 
[89]. The efects of eculizumab have not been documented 
in scleroderma-related aHUS. However, in a recent case 
report of SRC, in which diagnosis of aHUS was not ruled 
out or substantiated, treatment with eculizumab was associ-




Ulcerative colitis Diagnosis of aHUS in patients with 
gastrointestinal symptoms may require diferentiation from 
inlammatory bowel disorders such as ulcerative colitis 
(UC) [92]. Interestingly, alternative complement activation 
may also contribute to the pathogenesis of inlammatory 
bowel disorders. For example, it has been postulated that the 
upregulation of complement components may contribute to 
local inlammation and tissue damage in Crohn’s disease 
[93]. Inlammatory bowel disorders have been associated 
with upregulation of C3, which was strongly correlated with 
mucosal inlammation [94]. Deposition of C3b and the ter-
minal complement complex have also been demonstrated in 
mucosal tissue from patients with UC [95].
Only 2 cases of UC-associated aHUS have been reported 
in the literature (Table 1) [96, 97]. In the case reported by 
Green et al. [96], the patient was found to have complement 
factor H autoantibodies. Both patients were treated with 
eculizumab and had favorable outcomes with improvement 
in renal function and hematologic parameters [96, 97].
Drug-induced TMA
aHUS and other TMAs may develop subsequent to the use 
of certain medications and have been reviewed elsewhere 
[5]. Data from a recent systematic review showed that nine 
medications account for 76 % of TMA cases: quinine, tac-
rolimus, cyclosporine, interferons, gemcitabine, mitomy-
cin, clopidogrel, estrogen/progesterone, and ticlopidine 
[98]. The pathogenesis of drug-induced TMA involves 
two distinct mechanisms: immune mediated and direct 
toxicity. Evidence shows that quinine-, ticlopidine-, and 
clopidogrel-induced TMAs occur via an immune-mediated 
reaction, which is typically characterized by severe sys-
temic manifestations including anuric acute kidney injury. 
TMA caused by cyclosporine, gemcitabine, and mitomy-
cin occurs through a toxicity-mediated mechanism that is 
dose dependent and may also lead to renal impairment [98, 
99]. For TMA caused by cancer medications, onset may or 
may not be dose related and timing can vary from imme-
diately following therapy initiation to a 12-month delay 
[100]. Gemcitabine- and mitomycin-related TMA occur 
in <1 and 2‒15 % of patients, respectively, and outcomes 
may be quite poor: renal failure and/or mortality have been 
reported in up to 70–75 % of cases [101].
It is recommended that patients discontinue the medi-
cation if it is suspected to be the cause of TMA [1]. This 
approach should result in TMA resolution. Patients with 
TMA caused by immunosuppressants (e.g. cyclosporine, 
tacrolimus) should receive reduced doses or switch to 
another agent [102]. However, TMA may continue to pro-
gress despite the removal of an ofending agent, as has been 
documented with both mitomycin- [103] and tacrolimus-
induced TMA [104]. The optimal management strategy 
and timing for drug-induced TMA has not been estab-
lished, but it has been suggested that drug avoidance and 
supportive care may be the only beneicial options [1]. 
However, the role for PE/PI is unclear [100], and outcomes 
have included lack of improvement in or worsening renal 
function in mitomycin- [104], tacrolimus- [104, 105], and 
gemcitabine-induced TMA [106]. In these example cases, 
eculizumab therapy, sometimes in addition to anti-inlam-
matory agents, led to improvements in both hematologic 
parameters and renal function [103–106]. More studies are 
necessary to determine a potential role for eculizumab in 
drug-induced TMA.
Infection-induced TMA
Infections, particularly of the respiratory and gastrointesti-
nal tract, precede aHUS in approximately half of cases [4, 
9]. Common bacterial and viral infections associated with 
TMA have been reviewed elsewhere [5, 63] and include 
Streptococcus pneumoniae, cytomegalovirus, H1N1 inlu-
enza, human immunodeiciency virus, and parvovirus. 
Such infections are thought to activate the alternative path-
way of complement and may be associated with increased 
production of C5 and deposition of C5b-9 [63]. Clinical 
symptoms of some infections, including diarrhea, may 
complicate the diagnostic process [3, 5].
Diagnosis and management of TMA in patients 
with CACs
aHUS can be clinically identical to other TMAs, including 
STEC-HUS and TTP. No testing is available for deinitive 
diagnosis of aHUS [5]. In the setting of CACs and TMA, it 
may be particularly challenging to rule out other potential 
causes of TMA, including the existing CAC, to arrive at a 
diagnosis of aHUS [63]. It is possible that at the onset of 
aHUS, some patients with existing CACs may not present 
with all of the classic signs (i.e. thrombocytopenia, micro-
angiopathic hemolytic anemia, acute renal failure) [53].
An algorithm for the management of patients with CACs 
and TMA is presented in Fig.  1. In a patient presenting 
with TMA and a speciic CAC [9, 20, 24, 28, 53], clinicians 
should irst initiate speciic management for the identiied 
CAC, in order to treat underlying causes of TMA. If renal 
or extrarenal TMA arose from the CAC in the absence of 
complement dysregulation, TMA should resolve rapidly. 
As the French Study Group for aHUS/C3G (C3 glomeru-
lopathies) has recommended, resolution of renal TMA can 
be deined as normalization of platelet count and LDH 
level, and a decrease in serum creatinine by ≥25 % [63].
The persistence of TMA despite speciic management 
for the CAC strongly suggests that the CAC is lowering 
the threshold for manifestations and unmasking aHUS 
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[5, 24, 35, 53]. In these cases, diferential diagnosis of 
TMA is required [5]. All patients with TMA should have 
a thorough evaluation for underlying causes [5]. STEC-
HUS can be ruled out with a negative stool test for STEC. 
ADAMTS13 activity <5 % (depending on the assay used) 
indicates TTP [5]. Genetic investigations may help deter-
mine long-term prognosis of aHUS but are not required 
for diagnosis [5]. Complement gene mutations or factor 
H autoantibodies are identiied in approximately 50–70 % 
of patients with aHUS [4, 9]. The number of mutations 
characterized has been increasing steadily over recent 
years [107], and others may be identiied in the future.
Overall, clinicians should have a strong suspicion for 
aHUS in patients with ADAMTS13 activity ≥5 %, nega-
tive STEC test, and persistent TMA despite treatment 
of the CAC. It should be noted that testing results for 
ADAMTS13 activity level and STEC may not be rapidly 
available. Thus, some patients may initiate PE during the 
diferential diagnosis period [5] to temporarily maintain 
hematologic parameters, although it does not inhibit the 
underlying complement-mediated pathogenesis of aHUS 
[12] or prevent end-stage renal disease or mortality [9].
For patients with diagnosed aHUS, with or without 
a comorbid CAC, clinicians should initiate eculizumab 
therapy immediately according to established guidelines 
[5, 63, 108]. Clinical studies have shown that earlier 
intervention with eculizumab is associated with better 
renal outcomes for patients with aHUS [15]. The speciic 
efects of eculizumab in aHUS comorbid with individual 
CACs (e.g. autoimmune diseases) will be demonstrated 
as evidence accumulates in the literature.
The optimal treatment duration for patients with aHUS 
and speciic CACs has not been established. Expert and 
regulatory guidance notes that ongoing treatment may 
prevent risks of potentially life-threatening TMA that 
may occur following therapy discontinuation [5, 13, 14].
Conclusions
CACs are increasingly identiied in the medical literature 
as being comorbid with aHUS or unmasking previously 
undiagnosed cases. The presented case studies illustrate 
potential complexities in disease onset and diferential 
diagnosis when both a CAC and aHUS are present, as 
well as the beneits of eculizumab treatment for these 
patients. Overall, clinicians should consider a diagno-
sis of aHUS if TMA persists despite speciic manage-
ment for the CAC. Once aHUS is diagnosed, eculizumab 
should be initiated promptly to halt target organ injury 
and improve outcomes related to TMA.
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